Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04072263

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer (OVACURE)

Sponsor: Leiden University Medical Center

Interventions Carboplatin Interferon Alfa 2A Paclitaxel Tumor Infiltrating Lymphocytes (TIL)

Updated 7 times since 2019 Last updated: Mar 30, 2021 Started: Aug 1, 2018 Primary completion: Aug 1, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Ovarian Cancer Recurrent and is currently ongoing. Leiden University Medical Center leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2023 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
May 2021 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Mar 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2019 — Mar 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Leiden University Medical Center

Data source: Leiden University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leiden, Netherlands